Eli Lilly (LLY) shares fell nearly 4% on Friday as concerns about the initial sales performance of its newly FDA-approved weight loss pill, Foundayo, weighed on investor sentiment. Despite early optimism following the success of its injectable obesity treatment, Zepbound, Foundayo’s prescriptions totaled only 3,707 in its second week, significantly trailing Novo Nordisk’s Wegovy, which recorded 18,410 prescriptions in the same timeframe.
This sluggish start raises questions about Foundayo’s market potential and could impact Lilly’s stock performance in the short term. While the company has downplayed the significance of early sales data, the stark contrast with Wegovy’s performance highlights the competitive pressures in the obesity treatment sector. Analysts will be closely monitoring Foundayo’s sales trajectory to assess whether it can gain traction in the coming weeks.
For market professionals, the key takeaway is to remain vigilant regarding Foundayo’s performance, as it could influence investor confidence in Lilly’s growth prospects within the lucrative weight loss market.
Source: fool.com